On the impact of functional imaging accuracy on selective boosting IMRT

Physica Medica

Volumn 25, Issue 1, 2009, Pages 12-24

  Kim, Y ^a   Tome W A ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Dose painting; Functional imaging; IMRT; Selective boosting

Indexed keywords

EQUIPMENT DESIGN; FALSE POSITIVE REACTIONS; HUMANS; MALE; MEDICAL ONCOLOGY; MODELS, STATISTICAL; PROSTATIC NEOPLASMS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SENSITIVITY AND SPECIFICITY;

PERU TOMATO MOSAIC VIRUS;

EID: 60249083401     PISSN: 11201797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejmp.2007.12.001     Document Type: Article

References (52)

1. Chao K.S.C., Bosch W.R., Mutic S., Lewis J.S., Dehdashti F., Mintun M.A., et al. A novel approach to overcome hypoxic tumour resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 49 4 (2001) 1171-1182
2. De Meerleer G., Villeirs G., Bral S., Paelinck L., De Gersem W., Dekuyper P., et al. The magnetic resonance detected intraprostatic lesion in prostate cancer: planning and delivery of intensity-modulated radiotherapy. Radiother Oncol 75 3 (2005) 325-333
3. van Lin E.N., Fütterer J.J., Heijmink S.W., van der Vight L.P., Hoffmann A.L., van Kollenburg P., et al. IMRT boost dose planning on dominant intraprostatic lesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 65 1 (2006) 291-303
4. Tomé W.A., and Fowler J.F. Selective boosting of tumor subvolumes. Int J Radiat Oncol Biol Phys 48 2 (2000) 593-599
5. Kim Y., and Tomé W.A. Risk-adaptive optimization: selective boosting of high-risk tumor subvolumes. Int J Radiat Oncol Biol Phys 66 5 (2006) 1528-1542
6. Popple R.A., Ove R., and Shen S. Tumor control probability for selective boosting of hypoxic subvolumes, including the effect of reoxygenation. Int J Radiat Oncol Biol Phys 54 3 (2002) 921-927
7. Ling C.C., Humm J., Larson S., Amols H., Fuks Z., Leibel S., et al. Towards multidimensional radiotherapy (MD-CRT): biological imaging and biological conformality. Int J Radiat Oncol Biol Phys 47 3 (2000) 551-560
8. Bentzen S.M. Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 6 2 (2005) 112-117
9. Dawson L.A., and Sharpe M.B. Image-guided radiotherapy: rationale, benefits, and limitations. Lancet Oncol 7 10 (2006) 848-858
10. Song W., Schaly B., Bauman G., Battista J., and Van Dyk J. Image-guided adaptive radiation therapy (IGART): Radiobiological and dose escalation considerations for localized carcinoma of the prostate. Med Phys 32 7 (2005) 2193-2203
11. Brahme A. Optimized radiation therapy based on radiobiological objectives. Semin Radiat Oncol 9 1 (1999) 35-47
12. Wolbarst A.B., Sternick E.S., Curran B.H., and Dritschilo A. Optimized radiotherapy treatment planning using the complication probability factor (CPF). Int J Radiat Oncol Biol Phys 6 6 (1980) 723-728
13. Wang X.H., Mohan R., Jackson A., Leibel S.A., Fuks Z., and Ling C.C. Optimization of intensity-modulated 3D conformal treatment plans based on biological indices. Radiother Oncol 37 2 (1995) 140-152
14. Pickett B., Vigneault E., Kurhanewicz J., Verhey L., and Roach M. Static field intensity modulation to treat a dominant intraprostatic lesion to 90 Gy compared to seven field 3 dimentional radiotherapy. Int J Radiat Oncol Biol Phys 44 4 (1999) 921-929
15. Xia P., Pickett B., Vigneault E., Verhey L.J., and Roach III M. Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 51 1 (2001) 244-254
16. Grégoire V., Bol A., Geets X., and Lee J. Is PET-based treatment planning the new standard in modern radiotherapy? The head and neck paradigm. Semin Radiat Oncol 16 4 (2006) 232-238
17. Apisarnthanarax S., and Chao K.S.C. Current imaging paradigms in radiation oncology. Radiat Res 163 1 (2005) 1-25
18. Jerusalem G., Hustinx R., Beguin Y., and Fillet G. PET scan imaging in oncology. Eur J Cancer 39 11 (2003) 1525-1534
19. McNeal J.E., Redwine E.A., Freiha F.S., and Stamey T.A. Zonal distribution of prostatic adenocarcinoma: correlation with histopathologic pattern and direction of spread. Am J Surg Pathol 12 12 (1988) 897-906
20. Pollack A., Zagars G.K., Starkschall G., Antolak J.A., Lee J.J., Huang E., et al. Prostate cancer radiation dose response: Results of the M.D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53 5 (2002) 1097-1105
21. Burman C.M., Zelefsky M.J., and Leibel S.A. Treatment planning, dose delivery, and outcome of IMRT for localized prostate cancer. In: Hellman S., et al. (Ed). A practical guide to intensity-modulated radiation therapy (2003), Medical Physics Publishing, Madison, WI 169-190
22. Bentzen S.M., and Tucker S.L. Quantifying the position and steepness of radiation dose-response curves. Int J Radiat Biol 71 1 (1997) 531-542
23. Suit H.D., Shalek R.J., and Wette R. Radiation response of C3H mouse mammary carcinoma evaluated in terms of cellular radiation sensitivity. Cellular Radiation Biology (1965), Williams & Wilkins, Baltimore 514-530
24. Levegrün S.A., Jackson M.J., Zelefsky E.S., Venkatraman E.S., Skwarchuk M.W., Schlegel W., et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother Oncol 63 1 (2002) 11-26
25. Goitein M, Niemierko A, Okunieff P. The probability of controlling an inhomogeneously irradiated tumor. In: Kaulner K, Carey B, Crellin A, editors. Quantitative imaging in oncology. Proceedings of the 19th LH Gray Conference. London: British Institute of Radiology; 1995. p. 25-32.
26. Lyman J.T. Complication probability as assessed from dose-volume histograms. Radiat Res 8 (1985) S13-S19
27. Niemierko A. A generalized concept of equivalent uniform dose (EUD). Med Phys 26 6 (1999) 1100
28. Kutcher G.J., and Burman C. Calculation of complication probability factors for non-uniform normal tissue irradiation: the effective volume method. Int J Radiat Oncol Biol Phys 16 6 (1989) 1623-1630
29. Rancati T., Fiorino C., Gagliardi G., Cattaneo G.M., Sanguineti G., Borca V.C., et al. Fitting late rectal bleeding data using different NTCP models: results from an Italian multi-centric study (AIROPROS0101). Radiother Oncol 73 1 (2004) 21-32
30. Tucker S.L., Dong L., Cheung R., Johnson J., Mohan R., Huang E.H., et al. Comparison of rectal dose-wall histogram versus dose-volume histogram for modeling the incidence of late rectal bleeding after radiotherapy. Int J Radiat Oncol Biol Phys 60 5 (2004) 1589-1601
31. Munro T.R., and Gilbert C.W. The relation between tumour lethal doses and the radiosensitivity of tumour cells. Br. J Radiol 34 (1961) 246-251
32. Marks L.B., Carroll P.R., Dugan T.C., and Anscher M.S. The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 31 5 (1995) 1257-1280
33. Zietman A.L., DeSilvio M., Slater J.D., Rossi Jr. C.J., Miller D.W., Adams J.A., et al. Comparison of conventional dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 294 (2005) 1274-1276
34. Pollack A., Zagars G.K., Smith L.G., Lee J.J., von Eschenbach A.C., Antolak J.A., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 23 (2000) 3904-3911
35. Sathya J.R., Davis I.R., Julian J.A., Guo Q., Daya D., Dayes I.S., et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J Clin Oncol 23 6 (2005) 1192-1199
36. Lukka H., Hayter C., Julian J.A., Warde P., Morris W.J., Gospodarowicz M., et al. Randomized trial comparing two fractionation schemes for patients with localized prostate cancer. J Clin Oncol 23 25 (2005) 6132-6138
37. Jacob R., Hanlon A.L., Horwitz E.M., Movasas B., Uzzo R.G., and Rollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer 100 3 (2004) 538-543
38. Gambhir S.S., Czernin J., Schwimmer J., Silverman D.H., Coleman R.E., and Rhelps M.E. A tabulated summary of the FDG PET literature. J Nucl Med 42 5 suppl (2001) 1S-93S
39. Pieterman R.M., van Putten J.W., Meuzelaar J.J., Mooyaart E.L., Vaalburg W., Koëter G.H., et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 343 4 (2000) 254-261
40. Staib L., Schirrmeister H., Reske S.N., and Beger H.G. Is 18F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?. Am J Surg 180 1 (2000) 1-5
41. Scheidler J., Hricak H., Vigneron D.B., Yu K.K., Sokolov D.L., Huang L.R., et al. Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213 2 (1999) 473-480
42. Wefer A.E., Hricak H., Vigneron D.B., Coakley F.V., Lu Y., Wefer J., et al. Sextant localization of prostate cancer: Comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology. J Urol 164 2 (2000) 400-404
43. Buck A.K., Schirmeister H., Hetzel M., Von Der Heide M., Halter G., Glatting G., et al. 3-Deoxy-3-(18F)fluorothymidine-positron emission tomography for non-invasive assessment of proliferation in pulmonary nodules. Cancer Res 62 12 (2002) 3331-3334
44. Yap C.S., Czernin J., Fishbein M.C., Cameron R.B., Schiepers C., Phelps M.E., et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest 129 2 (2006) 393-401
45. 18F]-FDG-PET and PET-CT in the planning of radiotherapy for non-small cell lung cancer (NSCLC): the technical basis, ICRU-target volumes, problems, perspectives. Radiother Oncol 81 2 (2006) 209-225
46. 64Cu(II)-diacetyl-bis (N4-Methylthiosemicarbazone). J Nucl Med 47 6 (2006) 989-998
47. Smit W.G., Helle P.A., Van Putten W.L., Wijnmaalen A.J., Seldenrath J.J., and van der Werf-Messing B.H. Late radiation damage in prostate cancer patients treated by high dose external radiotherapy in relation to rectal dose. Int J Radiat Oncol Biol Phys 18 1 (1990) 23-29
48. Patel R.R., Orton N., Tomé W.A., Chappell R., and Ritter M.A. Rectal dose sparing with a balloon catheter and ultrasound localization in conformal radiation therapy for prostate cancer. Radiother Oncol 67 3 (2003) 285-294
49. Fiorino C., Sanguineti G., Cozzarini C., Fellin G., Foppiano F., Menegotti L., et al. Rectal dose-volume constraints in high-dose radiotherapy of localized prostate cancer. Int J Radiat Oncol Biol Phys 57 4 (2003) 953-962
50. Jackson A., Skwarchuk M.W., Zelefsky M.J., Cowen D.M., Venkatraman E.S., Levegrün S., et al. Late rectal bleeding after conformal radiotherapy of prostate cancer (II): Volume effects and dose-volume histograms. Int J Radiat Oncol Biol Phys 49 3 (2001) 685-698
51. Fiorino C., Cozzarini C., Vavassori V., Sanguineti G., Bianchi C., Cattaneo G.M., et al. Relationships between DVHs and late rectal bleeding after radiotherapy for prostate cancer: analysis of a large group of patients pooled from three institutions. Radiother Oncol 64 1 (2002) 1-12
52. Declich F., Masi L., Menegotti L., Stasi M., Fiorino C., and Manzoni A. Comparing rectal DVH calculation with four commercial treatment planning systems by means of the AAPM TG23 18MV unit. Radiother Oncol 64 suppl 1 (2002) S318